Jeffrey A Bluestone

List of Publications by Year
in descending order

94 papers	32,687 citations	13099 68 h-index	39675 94 g-index
102 all docs	102 docs citations	102 times ranked	30829 citing authors

#	Article	IF	Citations
1	The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. Frontiers in Immunology, 2021, 12, 639818.	4.8	60
2	Immunotherapy: Building a bridge to a cure for type 1 diabetes. Science, 2021, 373, 510-516.	12.6	81
3	The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight, 2021, 6, .	5.0	91
4	Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Frontiers in Immunology, 2021, 12, 686439.	4.8	37
5	Cutting Edge: IL-6â€"Driven Immune Dysregulation Is Strictly Dependent on IL-6R Î±-Chain Expression. Journal of Immunology, 2020, 204, 747-751.	0.8	5
6	Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nature Biotechnology, 2020, 38, 44-49.	17.5	198
7	Treg cell-based therapies: challenges and perspectives. Nature Reviews Immunology, 2020, 20, 158-172.	22.7	383
8	Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Science Immunology, 2020, 5, .	11.9	148
9	Tolerance in the Age of Immunotherapy. New England Journal of Medicine, 2020, 383, 1156-1166.	27.0	67
10	Accelerating the development of innovative cellular therapy products for the treatment of cancer. Cytotherapy, 2020, 22, 239-246.	0.7	7
11	CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature, 2020, 582, 416-420.	27.8	141
12	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet, The, 2020, 395, 1627-1639.	13.7	266
13	Functional CRISPR dissection of gene networks controlling human regulatory T cell identity. Nature Immunology, 2020, 21, 1456-1466.	14.5	57
14	Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model. PLoS ONE, 2019, 14, e0217728.	2.5	19
15	Next-generation regulatory T cell therapy. Nature Reviews Drug Discovery, 2019, 18, 749-769.	46.4	311
16	A Mutation in the Transcription Factor Foxp3 Drives T Helper 2 Effector Function in Regulatory T Cells. Immunity, 2019, 50, 362-377.e6.	14.3	72
17	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 603-613.	27.0	584
18	Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 431-440.	5.6	103

#	Article	IF	Citations
19	Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science, 2018, 359, 1037-1042.	12.6	254
20	Revealing the specificity of regulatory T cells in murine autoimmune diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5265-5270.	7.1	64
21	Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. Journal of Allergy and Clinical Immunology, 2018, 142, 1710-1718.	2.9	124
22	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunology Research, 2018, 6, 1445-1452.	3.4	132
23	T _{reg} cellsâ€"the next frontier of cell therapy. Science, 2018, 362, 154-155.	12.6	124
24	Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes, 2018, 67, 1471-1480.	0.6	386
25	A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nature Medicine, 2018, 24, 1005-1014.	30.7	165
26	Revisiting IL-2: Biology and therapeutic prospects. Science Immunology, 2018, 3, .	11.9	398
27	Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. Journal of Immunology, 2018, 201, 2094-2106.	0.8	58
28	Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Reports, 2018, 23, 3262-3274.	6.4	207
29	Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Molecular Therapy - Methods and Clinical Development, 2017, 4, 178-191.	4.1	62
30	FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance. Journal of Immunology, 2017, 198, 979-980.	0.8	13
31	Is autoimmunity the Achilles' heel of cancer immunotherapy?. Nature Medicine, 2017, 23, 540-547.	30.7	367
32	Targeting ABL-IRE1Î± Signaling Spares ER-Stressed Pancreatic Î² Cells to Reverse Autoimmune Diabetes. Cell Metabolism, 2017, 25, 883-897.e8.	16.2	149
33	Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 305-330.	22.4	54
34	Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature, 2017, 549, 111-115.	27.8	247
35	Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes. Frontiers in Immunology, 2017, 8, 1313.	4.8	81
36	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	4.8	43

#	Article	IF	Citations
37	CD28 Costimulation: From Mechanism to Therapy. Immunity, 2016, 44, 973-988.	14.3	607
38	Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2Âyear results of a randomised trial. Diabetologia, 2016, 59, 1153-1161.	6.3	72
39	Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease. Nature Reviews Immunology, 2016, 16, 149-163.	22.7	409
40	CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. Journal of Immunology, 2016, 196, 2051-2062.	0.8	103
41	Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. Journal of Immunology, 2015, 195, 145-155.	0.8	219
42	The Chromatin-Modifying Enzyme Ezh2 Is Critical for the Maintenance of Regulatory T Cell Identity after Activation. Immunity, 2015, 42, 227-238.	14.3	253
43	Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nature Immunology, 2015, 16, 188-196.	14.5	347
44	The immune system in Duchenne muscular dystrophy: Friend or foe. Rare Diseases (Austin, Tex), 2015, 3, e1010966.	1.8	59
45	Interleukin-33 and Interferon-Î³ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. Immunity, 2015, 43, 161-174.	14.3	368
46	Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10437-10442.	7.1	600
47	Shifting the Evolving CAR T Cell Platform into Higher Gear. Cancer Cell, 2015, 28, 401-402.	16.8	7
48	Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science Translational Medicine, 2015, 7, 315ra189.	12.4	767
49	Aberrant Innate Immune Activation following Tissue Injury Impairs Pancreatic Regeneration. PLoS ONE, 2014, 9, e102125.	2.5	36
50	Innate Antiviral Host Defense Attenuates TGF-Î² Function through IRF3-Mediated Suppression of Smad Signaling. Molecular Cell, 2014, 56, 723-737.	9.7	64
51	Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Science Translational Medicine, 2014, 6, 258ra142.	12.4	193
52	Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nature Medicine, 2014, 20, 62-68.	30.7	930
53	Interleukin-5â€"producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood, 2014, 124, 3572-3576.	1.4	100
54	Self-antigen-Driven Activation Induces Instability of Regulatory T Cells during an Inflammatory Autoimmune Response. Immunity, 2013, 39, 949-962.	14.3	326

#	Article	IF	Citations
55	Regulatory T-Cell Therapy in Transplantation: Moving to the Clinic. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015552-a015552.	6.2	190
56	Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune Diseases. Cold Spring Harbor Perspectives in Biology, 2012, 4, a007542-a007542.	5.5	59
57	Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. Journal of Experimental Medicine, 2012, 209, 1713-1722.	8.5	553
58	Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nature Immunology, 2011, 12, 898-907.	14.5	179
59	Regulatory T cells: stability revisited. Trends in Immunology, 2011, 32, 301-306.	6.8	95
60	Genetics, pathogenesis and clinical interventions in typeâ€‰1 diabetes. Nature, 2010, 464, 1293-1300.	27.8	998
61	The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nature Reviews Immunology, 2010, 10, 797-803.	22.7	55
62	IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. Journal of Experimental Medicine, 2010, 207, 1871-1878.	8.5	368
63	Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer. PLoS ONE, 2010, 5, e11726.	2.5	139
64	Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nature Immunology, 2009, 10, 1000-1007.	14.5	1,251
65	The functional plasticity of T cell subsets. Nature Reviews Immunology, 2009, 9, 811-816.	22.7	241
66	Expansion of Human Regulatory T-Cells From Patients With Type 1 Diabetes. Diabetes, 2009, 58, 652-662.	0.6	333
67	Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature, 2008, 455, 1109-1113.	27.8	1,745
68	The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nature Immunology, 2008, 9, 239-244.	14.5	880
69	Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction. Immunity, 2008, 28, 687-697.	14.3	646
70	Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. Journal of Experimental Medicine, 2008, 205, 1983-1991.	8.5	482
71	Murine Pancreatic Islet Isolation. Journal of Visualized Experiments, 2007, , 255.	0.3	96
72	Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice. Journal of Visualized Experiments, 2007, , 404.	0.3	73

#	Article	IF	Citations
73	CD3-specific antibodies: a portal to the treatment of autoimmunity. Nature Reviews Immunology, 2007, 7, 622-632.	22.7	361
74	Loss of integrin Î±vÎ²8 on dendritic cells causes autoimmunity and colitis in mice. Nature, 2007, 449, 361-365.	27.8	463
75	CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. Journal of Experimental Medicine, 2006, 203, 1701-1711.	8.5	2,292
76	Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nature Immunology, 2006, 7, 83-92.	14.5	718
77	Suppression of Disease in New Zealand Black/New Zealand White Lupus-Prone Mice by Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells. Journal of Immunology, 2006, 177, 1451-1459.	0.8	231
78	How do CD4+CD25+ regulatory T cells control autoimmunity?. Current Opinion in Immunology, 2005, 17, 638-642.	5.5	221
79	Expansion of Functional Endogenous Antigen-Specific CD4+CD25+ Regulatory T Cells from Nonobese Diabetic Mice. Journal of Immunology, 2005, 175, 3053-3059.	0.8	232
80	Sequential development of interleukin 2â€"dependent effector and regulatory T cells in response to endogenous systemic antigen. Journal of Experimental Medicine, 2005, 202, 1375-1386.	8.5	271
81	Therapeutic vaccination using CD4⁺CD25⁺antigen-specific regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14622-14626.	7.1	143
82	In Vitroâ€"expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes. Journal of Experimental Medicine, 2004, 199, 1455-1465.	8.5	1,082
83	Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus. New England Journal of Medicine, 2002, 346, 1692-1698.	27.0	1,118
84	ICOS costimulation: it's not just for TH2 cells anymore. Nature Immunology, 2001, 2, 573-574.	14.5	68
85	Effect of Immune Deficiency on Lipoproteins and Atherosclerosis in Male Apolipoprotein Eâ€"Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1011-1016.	2.4	165
86	Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation. Annual Review of Immunology, 2001, 19, 225-252.	21.8	973
87	B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes. Immunity, 2000, 12, 431-440.	14.3	1,884
88	The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunological Reviews, 1998, 164, 63-72.	6.0	159
89	The Efficiency of CD4 Recruitment to Ligand-engaged TCR Controls the Agonist/Partial Agonist Properties of Peptideâ€"MHC Molecule Ligands. Journal of Experimental Medicine, 1997, 185, 219-230.	8.5	166
90	CD28/B7 SYSTEM OF T CELL COSTIMULATION. Annual Review of Immunology, 1996, 14, 233-258.	21.8	2,466

#	Article	IF	Citations
91	Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunology, Immunotherapy, 1996, 42, 161-169.	4.2	25
92	The Complexities of T-Cell Co-stimulation: CD28 and Beyond. Immunological Reviews, 1996, 153, 155-182.	6.0	142
93	TCRÎ³Î´ cells: Mysterious cells of the immune system. Immunologic Research, 1994, 13, 268-279.	2.9	22
94	Anti-CD3 therapy enhances hematopoiesis and blocks graft-versus-host disease. International Journal of Cell Cloning, 1991, 9, 91-104.	1.6	0